Published in J Clin Oncol on August 05, 2013
Apatinib for Metastatic Esophageal Cancer. | NCT02544737
Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy | NCT02711007
Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma | NCT02704767
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | NCT03104335
Apatinib in Refractory Colorectal Cancer | NCT03190616
Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med (2014) 1.24
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One (2014) 1.03
Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol (2014) 1.02
Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer (2014) 0.99
Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther (2015) 0.98
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget (2015) 0.97
Pathogenetic mechanisms in gastric cancer. World J Gastroenterol (2014) 0.97
Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol (2015) 0.92
Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. Onco Targets Ther (2015) 0.89
Chemotherapy beyond second-line in advanced gastric cancer. World J Gastroenterol (2015) 0.88
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature. Medicine (Baltimore) (2016) 0.87
Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Sci Rep (2015) 0.87
Gastric Carcinogenesis and Underlying Molecular Mechanisms: Helicobacter pylori and Novel Targeted Therapy. Biomed Res Int (2015) 0.87
Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol (2016) 0.86
Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf) (2015) 0.85
A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer. Medicine (Baltimore) (2015) 0.85
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? Cancer Biol Ther (2015) 0.83
Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol (2015) 0.82
Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget (2016) 0.82
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol (2016) 0.81
New advances in targeted gastric cancer treatment. World J Gastroenterol (2016) 0.81
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget (2016) 0.79
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol (2016) 0.79
Metastatic gastric cancer treatment: Second line and beyond. World J Gastroenterol (2016) 0.79
Gastric cancer: The times they are a-changin'. World J Gastrointest Oncol (2015) 0.79
Clinical utility of ramucirumab in advanced gastric cancer. Biologics (2015) 0.79
Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. Medicine (Baltimore) (2016) 0.79
miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis (2016) 0.78
The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol (2017) 0.78
Gastric Cancer: New Drugs - New Strategies. Gastrointest Tumors (2015) 0.78
Inhibition of β-catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo. Gastric Cancer (2014) 0.78
Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer Metastasis Rev (2016) 0.78
Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage. Int J Nanomedicine (2016) 0.77
Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer. Oncotarget (2016) 0.77
The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. Am J Cancer Res (2015) 0.77
Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs (2016) 0.77
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterol Res Pract (2016) 0.77
What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol (2014) 0.76
Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers. Ther Clin Risk Manag (2015) 0.76
Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget (2017) 0.76
Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series. Onco Targets Ther (2017) 0.75
HER2/neu as target in gastric adenocarcinoma. Transl Gastroenterol Hepatol (2016) 0.75
Hypoxia Promotes Gastric Cancer Malignancy Partly through the HIF-1α Dependent Transcriptional Activation of the Long Non-coding RNA GAPLINC. Front Physiol (2016) 0.75
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report. Onco Targets Ther (2017) 0.75
Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther (2017) 0.75
The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. PLoS One (2017) 0.75
Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts. Oncol Lett (2016) 0.75
A case report of apatinib in treating osteosarcoma with pulmonary metastases. Medicine (Baltimore) (2017) 0.75
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer. Transl Gastroenterol Hepatol (2017) 0.75
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. Br J Cancer (2016) 0.75
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget (2017) 0.75
Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs (2015) 0.75
Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. J Hematol Oncol (2016) 0.75
Clinical modalities for management of gastric cancer hepatic metastasis. Int J Clin Exp Med (2015) 0.75
Targeted therapies: Hope for antiangiogenic therapy in advanced gastric cancer. Nat Rev Clin Oncol (2013) 0.75
Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma. Oncotarget (2016) 0.75
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes. Am J Cancer Res (2017) 0.75
Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget (2017) 0.75
Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. Onco Targets Ther (2017) 0.75
Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore) (2017) 0.75
Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget (2017) 0.75
Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review. J Hematol Oncol (2017) 0.75
Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget (2017) 0.75
Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study. Sci Rep (2017) 0.75
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity (2008) 7.60
The European Nucleotide Archive. Nucleic Acids Res (2010) 6.48
Resequencing of 31 wild and cultivated soybean genomes identifies patterns of genetic diversity and selection. Nat Genet (2010) 5.20
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Improvements to services at the European Nucleotide Archive. Nucleic Acids Res (2009) 5.00
Resequencing 50 accessions of cultivated and wild rice yields markers for identifying agronomically important genes. Nat Biotechnol (2011) 4.84
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N Engl J Med (2009) 3.88
Hyperspectral remote sensing of foliar nitrogen content. Proc Natl Acad Sci U S A (2012) 3.87
Maize HapMap2 identifies extant variation from a genome in flux. Nat Genet (2012) 3.74
Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet (2010) 3.69
The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu Rev Immunol (2007) 3.59
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med (2009) 3.32
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science (2008) 3.17
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology (2002) 3.02
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol (2012) 2.98
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol (2011) 2.87
Draft genome of the wheat A-genome progenitor Triticum urartu. Nature (2013) 2.86
Genome sequence of foxtail millet (Setaria italica) provides insights into grass evolution and biofuel potential. Nat Biotechnol (2012) 2.82
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci (2007) 2.75
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res (2005) 2.67
Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis (2005) 2.62
Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A (2008) 2.60
DELLAs modulate jasmonate signaling via competitive binding to JAZs. Dev Cell (2010) 2.58
An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol Cell (2007) 2.57
Regulation of floral patterning by flowering time genes. Dev Cell (2009) 2.56
Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation (2007) 2.50
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
Sequencing and automated whole-genome optical mapping of the genome of a domestic goat (Capra hircus). Nat Biotechnol (2012) 2.45
Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Mol Cell Biol (2002) 2.45
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol (2013) 2.44
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma (2011) 2.37
Multiple genes for essential-hypertension susceptibility on chromosome 1q. Am J Hum Genet (2006) 2.34
Chinese physicians and their smoking knowledge, attitudes, and practices. Am J Prev Med (2007) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Methods of the International Tobacco Control (ITC) China Survey. Tob Control (2009) 2.30
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
A repressor complex governs the integration of flowering signals in Arabidopsis. Dev Cell (2008) 2.24
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity (2009) 2.21
The GUDMAP database--an online resource for genitourinary research. Development (2011) 2.20
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res (2004) 2.07
Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol (2013) 2.06
A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci (2006) 2.04
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med (2012) 2.04
The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) (2008) 2.04
Characterizing the risk assessment of heavy metals and sampling uncertainty analysis in paddy field by geostatistics and GIS. Environ Pollut (2005) 2.00
Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res (2011) 1.99
Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab (2005) 1.99
The homeotic protein AGAMOUS controls microsporogenesis by regulation of SPOROCYTELESS. Nature (2004) 1.98
Major submissions tool developments at the European Nucleotide Archive. Nucleic Acids Res (2011) 1.94
Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J Neurosci (2010) 1.93
Purple acid phosphatases of Arabidopsis thaliana. Comparative analysis and differential regulation by phosphate deprivation. J Biol Chem (2002) 1.93
Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol (2003) 1.93
CEACAM1 regulates insulin clearance in liver. Nat Genet (2002) 1.92
Forecasting global generation of obsolete personal computers. Environ Sci Technol (2010) 1.89
Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release (2011) 1.89
Cardiac Na+ current regulation by pyridine nucleotides. Circ Res (2009) 1.87
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res (2004) 1.84
Deletion of the neuron-specific protein delta-catenin leads to severe cognitive and synaptic dysfunction. Curr Biol (2004) 1.80
Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum Mol Genet (2003) 1.80
Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci (2009) 1.80
Cooperative shear model for the rheology of glass-forming metallic liquids. Phys Rev Lett (2006) 1.77
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol (2012) 1.76
The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol (2008) 1.75
Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol (2005) 1.74
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol (2012) 1.73
Comparisons of image quality and radiation dose between iterative reconstruction and filtered back projection reconstruction algorithms in 256-MDCT coronary angiography. AJR Am J Roentgenol (2012) 1.73
3D noncontrast MR angiography of the distal lower extremities using flow-sensitive dephasing (FSD)-prepared balanced SSFP. Magn Reson Med (2009) 1.72
8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet (2008) 1.72
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res (2010) 1.71
Extensive DNA damage-induced sumoylation contributes to replication and repair and acts in addition to the mec1 checkpoint. Mol Cell (2012) 1.70
L-fucose utilization provides Campylobacter jejuni with a competitive advantage. Proc Natl Acad Sci U S A (2011) 1.68
The Relationship between auxin transport and maize branching. Plant Physiol (2008) 1.68
Specification of Arabidopsis floral meristem identity by repression of flowering time genes. Development (2007) 1.68
Direct interaction of AGL24 and SOC1 integrates flowering signals in Arabidopsis. Development (2008) 1.66
GJB2 mutation spectrum in 2,063 Chinese patients with nonsyndromic hearing impairment. J Transl Med (2009) 1.66